Agios Pharmaceuticals (NASDAQ:AGIO) SVP Glenn Goddard sold 2,000 shares of Agios Pharmaceuticals stock on the open market in a transaction dated Monday, April 7th. The stock was sold at an average price of $45.17, for a total transaction of $90,340.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares after opening at $44.45 moved to $46.00 on last trade day and at the end of the day closed at $43.32. Company price to sales ratio in past twelve months was calculated as 53.67 and price to cash ratio as 8.20. Agios Pharmaceuticals Inc (NASDAQ:AGIO) showed a positive weekly performance of 22.10%.
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Questcor Pharmaceuticals Inc (NASDAQ:QCOR) in connection with the sale of the Company to Mallinckrodt. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) shares fell -2.20% in last trading session and ended the day on $80.12. QCOR return on equity ratio is recorded as 94.20% and its return on assets is 50.60%. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) yearly performance is 190.40%.
Mar 24, 2014 Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) A biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, reported its financial results and business highlights for the fourth quarter and year ended December 31, 2013.Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) shares moved up 1.81% in last trading session and was closed at $58.99, while trading in range of $56.31-$60.00. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) year to date performance is 39.62%.
Clinipace Worldwide, a global digital clinical research organization (dCRO) , announced that Karyopharm Therapeutics Inc (NASDAQ:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology, wound healing, and other diseases. Karyopharm Therapeutics Inc (NASDAQ:KPTI) weekly performance is 15.37%. On last trading day company shares ended up $34.31. Karyopharm Therapeutics Inc (NASDAQ:KPTI) distance from 50-day simple moving average is -6.32%. Analysts mean target price for the company is $48.33.